BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dendl K, Koerber SA, Kratochwil C, Cardinale J, Finck R, Dabir M, Novruzov E, Watabe T, Kramer V, Choyke PL, Haberkorn U, Giesel FL. FAP and FAPI-PET/CT in Malignant and Non-Malignant Diseases: A Perfect Symbiosis? Cancers (Basel) 2021;13:4946. [PMID: 34638433 DOI: 10.3390/cancers13194946] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Laferriere-holloway TS, Rios A, Carlucci G, van Dam RM. Rapid Purification and Formulation of Radiopharmaceuticals via Thin-Layer Chromatography. Molecules 2022;27:8178. [DOI: 10.3390/molecules27238178] [Reference Citation Analysis]
2 Laferriere-holloway TS, Rios A, Lu Y, Okoro CC, van Dam RM. A rapid and systematic approach for the optimization of radio thin-layer chromatography resolution. Journal of Chromatography A 2022. [DOI: 10.1016/j.chroma.2022.463656] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Beyhan E, Erol Fenercioğlu Ö, Yarikkaya E, Çermik TF, Ergül N. Chronic Gastritis Mimicking Malignancy on 68Ga-FAPI-04 PET/CT. Clin Nucl Med 2022. [PMID: 36240789 DOI: 10.1097/RLU.0000000000004439] [Reference Citation Analysis]
4 Mu X, Huang X, Li M, Sun W, Fu W. Comparison of physiological uptake of normal tissues in patients with cancer using 18F-FAPI-04 and 18F-FAPI-42 PET/CT. Front Nucl Med 2022;2. [DOI: 10.3389/fnume.2022.927843] [Reference Citation Analysis]
5 Califaretti E, Dall’armellina S, Rovera G, Finessi M, Deandreis D. The role of PET/CT in thyroid autoimmune diseases. Q J Nucl Med Mol Imaging 2022;66. [DOI: 10.23736/s1824-4785.22.03464-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Dendl K, Koerber SA, Tamburini K, Mori Y, Cardinale J, Haberkorn U, Giesel FL. Advancement and Future Perspective of FAPI PET/CT In Gynecological Malignancies. Semin Nucl Med 2022;52:628-34. [PMID: 35842334 DOI: 10.1053/j.semnuclmed.2022.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lyu Z, Han W, Zhao H, Jiao Y, Xu P, Wang Y, Shen Q, Yang S, Zhao C, Tian L, Fu P. A clinical study on relationship between visualization of cardiac fibroblast activation protein activity by Al18F-NOTA-FAPI-04 positron emission tomography and cardiovascular disease. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.921724] [Reference Citation Analysis]
8 Veldhuijzen van Zanten SEM, Pieterman KJ, Wijnhoven BPL, Pruis IJ, Groot Koerkamp B, van Driel LMJW, Verburg FA, Thomeer MGJ. FAPI PET versus FDG PET, CT or MRI for Staging Pancreatic-, Gastric- and Cholangiocarcinoma: Systematic Review and Head-to-Head Comparisons of Diagnostic Performances. Diagnostics 2022;12:1958. [DOI: 10.3390/diagnostics12081958] [Reference Citation Analysis]
9 Dondi F, Albano D, Treglia G, Bertagna F. Emerging Role of FAPI PET Imaging for the Assessment of Benign Bone and Joint Diseases. JCM 2022;11:4514. [DOI: 10.3390/jcm11154514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Novruzov E, Mori Y, Antke C, Dabir M, Schmitt D, Kratochwil C, Koerber SA, Haberkorn U, Giesel FL. A Role of Non-FDG Tracers in Lung Cancer? Semin Nucl Med 2022:S0001-2998(22)00054-X. [PMID: 35803770 DOI: 10.1053/j.semnuclmed.2022.05.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Fu H, Wu J, Huang J, Sun L, Wu H, Guo W, Qiu S, Chen H. 68Ga Fibroblast Activation Protein Inhibitor PET/CT in the Detection of Metastatic Thyroid Cancer: Comparison with 18F-FDG PET/CT. Radiology 2022;:212430. [PMID: 35536131 DOI: 10.1148/radiol.212430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Nardone V, Desideri I, D’ambrosio L, Morelli I, Visani L, Di Giorgio E, Guida C, Clemente A, Belfiore MP, Cioce F, Spadafora M, Vinciguerra C, Mansi L, Reginelli A, Cappabianca S. Nuclear medicine and radiotherapy in the clinical management of glioblastoma patients. Clin Transl Imaging. [DOI: 10.1007/s40336-022-00495-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Unterrainer LM, Lindner S, Eismann L, Casuscelli J, Gildehaus FJ, Bui VN, Albert NL, Holzgreve A, Beyer L, Todica A, Brendel M, Cyran CC, Karl A, Stief CG, Ledderose ST, Unterrainer M, Bartenstein P, Wenter V, Kretschmer A. Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma. Eur J Nucl Med Mol Imaging 2022. [PMID: 35325283 DOI: 10.1007/s00259-022-05761-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Bijlstra OD, Boreel MME, van Mossel S, Burgmans MC, Kapiteijn EHW, Oprea-lager DE, Rietbergen DDD, van Velden FHP, Vahrmeijer AL, Swijnenburg R, Mieog JSD, de Geus-oei L. The Value of 18F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review. Diagnostics 2022;12:715. [DOI: 10.3390/diagnostics12030715] [Reference Citation Analysis]
15 Bruckmann NM, Morawitz J, Fendler WP, Ruckhäberle E, Bittner A, Giesel FL, Herrmann K, Antoch G, Umutlu L, Kirchner J. A Role of PET/MR in Breast Cancer? Seminars in Nuclear Medicine 2022. [DOI: 10.1053/j.semnuclmed.2022.01.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Franquet E, Park H. Molecular imaging in oncology: Common PET/CT radiopharmaceuticals and applications. European Journal of Radiology Open 2022;9:100455. [DOI: 10.1016/j.ejro.2022.100455] [Reference Citation Analysis]